ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care

There are over 100 therapies being tested in clinical trials for Alzheimer’s disease (AD) today. With therapies undergoing regulatory review and a growing DRUG DEVELOPMENT pipeline, the field is entering a new era of molecular‐specific therapies. A national registry represents an opportunity to evaluate the longitudinal outcomes of patients treated with any novel FDA‐approved AD therapy in real‐world settings, to inform clinical practice.